Status:
COMPLETED
Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198
Lead Sponsor:
Brii Biosciences Limited
Collaborating Sponsors:
TSB Therapeutics (Beijing) CO.LTD
Conditions:
COVID-19
Eligibility:
All Genders
18-49 years
Phase:
PHASE1
Brief Summary
This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
Eligibility Criteria
Inclusion
- Subject must be 18 to 49 years of age inclusive;
- Body weight ≤100 kg and body mass index (BMI) within the range of 19.0-24.0kg/m2 (inclusive);
- Male or female;
Exclusion
- Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation;
- A history of significant hypersensitivity, intolerance, or allergy to any drug compound;
- History of alcohol or other substance abuse;
Key Trial Info
Start Date :
July 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 3 2021
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04479644
Start Date
July 13 2020
End Date
February 3 2021
Last Update
March 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Beijing, Beijing Municipality, China